Cold Genesys completes $22 M Series C Funding
March 19, 2019 | Tuesday | News
The financing will accelerate the growth of Cold Genesys' ongoing clinical programs
Cold Genesys, Inc., a clinical-stage biopharmaceutical company focused on the development of novel immunotherapies, announced the closing of a $22 million Series C preferred stock financing. New investors participated in the round, including lead investor, ORI Healthcare Fund L.P. ("ORI Fund"), with participation from Perseverance Capital Management.
The financing will accelerate the growth of Cold Genesys' ongoing clinical programs and the continued advancement of its lead oncolytic immunotherapy CG0070, which has completed a Phase 2 study (BOND2) and demonstrated clinical safety and efficacy in over 100 patients to date for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).
